Natco pharma will endorse generic pomalidomide capsules under its brand name POMALID in India. The price of this generic medicine is Rs. 5000 for 1 mg capsule, Rs. 10,000 for 2 mg and Rs. 20,000 for 4mg capsule for a monthly pack of 21 capsules.
Natco Pharma on May 10, 2017 said it has launched a generic medicine pomalidomide for blood cancer in India. This drug is sold under brand name Pomalyst by Celegene in the US. It is a thalidomide analogue indicated, in mixture with dexamethasone, for patients with multiple myeloma which is a type of blood cancer and who have received minimum two therapies including a proteasome inhibitor and lenalidomide previously and have experienced disease progression on or within 60 days after the last therapy was completed.
"We believe, this is approximately 98 percent discount of price from what it is sold at in the USA to patients, per secondary market data researched," Natco claimed.
This latest blood cancer drug is expected to build up Natco’s oncology portfolio is much stronger aspect. Natco obtains approx one-third of its revenue from its oncology segment. Natco’s revenue was Rs. 1152.8 crore in the financial year of 2016. The portfolio of Oncology of Natco has grown 30 percent in the financial year 2016.
Share
